title: Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus.
abstract: Patients with type 2 diabetes mellitus are at risk for accelerated cognitive decline and dementia. Furthermore, their risk of stroke is increased and their outcome after stroke is worse than in those without diabetes. Incretin-based therapies are a class of antidiabetic agents that are of interest in relation to these cerebral complications of diabetes. Two classes of incretin-based therapies are currently available: the glucagon-like-peptide-1 agonists and the dipeptidyl peptidase-4 -inhibitors. Independent of their glucose-lowering effects, incretin-based therapies might also have direct or indirect beneficial effects on the brain. In the present review, we discuss the potential of incretin-based therapies in relation to dementia, in particular Alzheimer's disease, and stroke in patients with type 2 diabetes. Experimental studies on Alzheimer's disease have found beneficial effects of incretin-based therapies on cognition, synaptic plasticity and metabolism of amyloid-β and microtubule-associated protein tau. Preclinical studies on incretin-based therapies in stroke have shown an improved functional outcome, a reduction of infarct volume as well as neuroprotective and neurotrophic properties. Both with regard to the treatment of Alzheimer's disease, and with regard to prevention and treatment of stroke, randomized controlled trials in patients with or without diabetes are underway. In conclusion, experimental studies show promising results of incretin-based therapies at improving the outcome of Alzheimer's disease and stroke through glucose-independent pleiotropic effects on the brain. If these findings would indeed be confirmed in large clinical randomized controlled trials, this would have substantial impact.
authors.affiliation: University Medical Center Utrecht Brain Center Rudolf Magnus Department of Neurology Utrecht the Netherlands.
authors.forename: Onno N
authors.initials: ON
authors.lastname: Groeneveld
authors.affiliation: University Medical Center Utrecht Brain Center Rudolf Magnus Department of Neurology Utrecht the Netherlands.
authors.forename: L Jaap
authors.initials: LJ
authors.lastname: Kappelle
authors.affiliation: University Medical Center Utrecht Brain Center Rudolf Magnus Department of Neurology Utrecht the Netherlands.
authors.forename: Geert Jan
authors.initials: GJ
authors.lastname: Biessels
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods; D003704:Dementia / Q000188:drug therapy* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D054795:Incretins / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D052216:Glucagon-Like Peptide 1
keywords: Dementia; Incretins; Stroke
references.citation: Endocr Connect. 2015 Jun;4(2):R16-24
references.pmid: 25712899
references.citation: Expert Opin Investig Drugs. 2006 Aug;15(8):887-95
references.pmid: 16859392
references.citation: Cell Mol Life Sci. 2010 Nov;67(21):3711-23
references.pmid: 20496097
references.citation: Diabetes. 2015 May;64(5):1804-17
references.pmid: 25524911
references.citation: Alzheimers Res Ther. 2013 Apr 19;5(2):20
references.pmid: 23601582
references.citation: Behav Brain Res. 2009 Dec 14;205(1):265-71
references.pmid: 19573562
references.citation: J Diabetes Investig. 2016 Jan;7(1):5-16
references.pmid: 26816596
references.citation: Brain Res. 2012 Jan 3;1427:23-34
references.pmid: 22055454
references.citation: Brain Pathol. 2014 Apr;24(3):261-9
references.pmid: 24329968
references.citation: Biochim Biophys Acta. 2009 May;1792(5):470-81
references.pmid: 18848880
references.citation: Intern Med J. 2012 May;42(5):484-91
references.pmid: 22372522
references.citation: Eur J Pharmacol. 2010 Mar 25;630(1-3):158-62
references.pmid: 20035739
references.citation: Neurochem Int. 2007 Nov-Dec;51(6-7):361-9
references.pmid: 17629357
references.citation: Diabetes. 2013 Apr;62(4):1289-96
references.pmid: 23209191
references.citation: Eur J Pharmacol. 2012 Jan 15;674(2-3):280-6
references.pmid: 22115895
references.citation: N Engl J Med. 2013 Oct 3;369(14):1327-35
references.pmid: 23992602
references.citation: Neurobiol Aging. 2013 Feb;34(2):576-88
references.pmid: 22592020
references.citation: J Physiol Pharmacol. 2013 Oct;64(5):613-23
references.pmid: 24304575
references.citation: J Nutr Health Aging. 2011 Jun;15(6):445-9
references.pmid: 21623465
references.citation: Neuroscience. 2009 Sep 15;162(4):1212-9
references.pmid: 19463904
references.citation: J Neurophysiol. 2011 Apr;105(4):1574-80
references.pmid: 21273318
references.citation: Cell Metab. 2011 Mar 2;13(3):320-30
references.pmid: 21356521
references.citation: Cochrane Database Syst Rev. 2014 Jan 23;(1):CD005346
references.pmid: 24453023
references.citation: Neurosci Lett. 2008 Oct 31;444(3):217-21
references.pmid: 18760331
references.citation: J Mol Neurosci. 2002 Feb-Apr;18(1-2):7-14
references.pmid: 11931352
references.citation: J Endocrinol. 2013 May 28;218(1):1-11
references.pmid: 23591914
references.citation: J Neurochem. 2014 Feb;128(3):459-71
references.pmid: 24112036
references.citation: Int J Dev Neurosci. 2006 Nov;24(7):419-24
references.pmid: 17045447
references.citation: J Alzheimers Dis. 2013;35(2):267-83
references.pmid: 23568101
references.citation: Neurosci Lett. 2010 Dec 3;486(1):38-42
references.pmid: 20854877
references.citation: J Clin Invest. 2005 Dec;115(12):3554-63
references.pmid: 16322793
references.citation: J Neurosci Res. 2008 Feb 1;86(2):326-38
references.pmid: 17803225
references.citation: Neuroscience. 2010 Nov 10;170(4):1239-48
references.pmid: 20727946
references.citation: N Engl J Med. 2013 Oct 3;369(14):1317-26
references.pmid: 23992601
references.citation: J Clin Endocrinol Metab. 2009 Mar;94(3):846-52
references.pmid: 19088168
references.citation: Endocrinology. 2009 Jul;150(7):2997-3001
references.pmid: 19389830
references.citation: J Diabetes Investig. 2013 Mar 18;4(2):108-30
references.pmid: 24843641
references.citation: Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1285-90
references.pmid: 19164583
references.citation: Lancet Neurol. 2009 Nov;8(11):1006-18
references.pmid: 19782001
references.citation: J Neurophysiol. 2008 Apr;99(4):1590-5
references.pmid: 18234983
references.citation: J Clin Invest. 2012 Apr;122(4):1316-38
references.pmid: 22476197
references.citation: Behav Pharmacol. 2010 Sep;21(5-6):394-408
references.pmid: 20574409
references.citation: Int J Mol Sci. 2015 Mar 04;16(3):4973-84
references.pmid: 25749474
references.citation: Neuropharmacology. 2013 Sep;72:291-300
references.pmid: 23603201
references.citation: Int J Obes (Lond). 2010 Aug;34(8):1341-4
references.pmid: 20351729
references.citation: Diabetes Care. 2015 Jan;38(1):140-9
references.pmid: 25538310
references.citation: Diabetologia. 2015 May;58(5):1091-9
references.pmid: 25660260
references.citation: Lancet Diabetes Endocrinol. 2014 Mar;2(3):256-62
references.pmid: 24622756
references.citation: Int J Mol Sci. 2013 Oct 30;14(11):21513-24
references.pmid: 24177570
references.citation: Cochrane Database Syst Rev. 2013 Nov 11;(11):CD008143
references.pmid: 24214280
references.citation: Stroke. 2008 Oct;39(10):2727-31
references.pmid: 18658031
references.citation: Lancet Neurol. 2015 Apr;14(4):388-405
references.pmid: 25792098
references.citation: J Alzheimers Dis. 2010;19(4):1205-19
references.pmid: 20308787
references.citation: Neuroscience. 2013 Jan 3;228:294-300
references.pmid: 23103794
references.citation: BMJ. 2011 Jul 26;343:d4169
references.pmid: 21791495
references.citation: Lancet. 2011 Mar 19;377(9770):1019-31
references.pmid: 21371747
references.citation: J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):87-94
references.pmid: 24970907
references.citation: BMJ. 2012 Mar 12;344:e1369
references.pmid: 22411919
references.citation: Lancet. 2006 Nov 11;368(9548):1696-705
references.pmid: 17098089
references.citation: Minerva Endocrinol. 2006 Jun;31(2):133-47
references.pmid: 16682937
references.citation: J Cereb Blood Flow Metab. 2011 Aug;31(8):1696-705
references.pmid: 21487412
references.citation: Eur J Neurosci. 2013 Mar;37(5):839-49
references.pmid: 23240760
references.citation: Diabetes. 2004 Sep;53(9):2492-500
references.pmid: 15331566
references.citation: Clin Sci (Lond). 2012 May 1;122(10):473-83
references.pmid: 22150224
references.citation: J Neurosci. 2005 Feb 16;25(7):1816-25
references.pmid: 15716418
references.citation: J Pharmacol Exp Ther. 2002 Sep;302(3):881-8
references.pmid: 12183643
references.citation: Stroke. 2001 Oct;32(10):2426-32
references.pmid: 11588337
references.citation: Nat Med. 2003 Sep;9(9):1173-9
references.pmid: 12925848
references.citation: Am J Med. 2011 Jan;124(1 Suppl):S3-18
references.pmid: 21194578
references.citation: Neurobiol Aging. 2012 Feb;33(2):265-76
references.pmid: 20359773
references.citation: Stroke. 2009 Feb;40(2):604-9
references.pmid: 19023097
references.citation: J Neurosci Res. 2011 Jul;89(7):1103-13
references.pmid: 21472764
references.citation: Acta Pharmacol Sin. 2009 Feb;30(2):159-65
references.pmid: 19151742
references.citation: Int J Obes Relat Metab Disord. 2003 Mar;27(3):313-8
references.pmid: 12629557
references.citation: J Neurochem. 2007 Apr;101(1):41-56
references.pmid: 17394460
references.citation: Biopharm Drug Dispos. 2009 Jul;30(5):229-40
references.pmid: 19562682
references.citation: Neurobiol Dis. 2012 Apr;46(1):52-8
references.pmid: 22245388
references.citation: N Engl J Med. 2009 Jan 8;360(2):129-39
references.pmid: 19092145
references.citation: Cell Death Dis. 2013 May 02;4:e612
references.pmid: 23640454
references.citation: Eur J Pharmacol. 2013 Nov 5;719(1-3):170-179
references.pmid: 24070815
references.citation: Gastroenterology. 2007 May;132(6):2131-57
references.pmid: 17498508
references.citation: Nat Rev Neurol. 2010 Mar;6(3):145-55
references.pmid: 20157308
references.citation: J Pharm Pharmacol. 2013 Dec;65(12):1773-84
references.pmid: 24117480
references.citation: Lancet Neurol. 2015 Mar;14(3):329-40
references.pmid: 25728442
references.citation: Ann N Y Acad Sci. 2011 Dec;1243:E55-74
references.pmid: 22545749
references.citation: Cardiovasc Diabetol. 2015 May 21;14:57
references.pmid: 25990013
references.citation: Eur J Pharmacol. 2008 Jun 10;587(1-3):112-7
references.pmid: 18466898
references.citation: J Alzheimers Dis. 2013;37(3):623-35
references.pmid: 24008687
references.citation: J Neurosci. 2011 Apr 27;31(17):6587-94
references.pmid: 21525299
references.citation: Lancet. 2009 May 23;373(9677):1798-807
references.pmid: 19465235
references.citation: J Neurosci. 2012 Oct 3;32(40):13701-8
references.pmid: 23035082
references.citation: Diabetes. 2008 Aug;57(8):2046-54
references.pmid: 18487451
references.citation: PLoS One. 2013;8(3):e58181
references.pmid: 23472157
references.citation: Lancet. 2010 Jun 26;375(9733):2215-22
references.pmid: 20609967
references.citation: J Neurochem. 2010 Jun;113(6):1621-31
references.pmid: 20374430
references.citation: Br J Pharmacol. 2010 Feb 1;159(3):495-501
references.pmid: 20128800
references.citation: Exp Gerontol. 2010 Mar;45(3):202-7
references.pmid: 20005285
references.citation: J Neurosci Res. 2003 Jun 1;72(5):603-12
references.pmid: 12749025
references.citation: N Engl J Med. 2015 Jul 16;373(3):232-42
references.pmid: 26052984
references.citation: Neuropeptides. 1999 Jun;33(3):212-5
references.pmid: 10657494
references.citation: BMC Neurosci. 2012 Mar 23;13:33
references.pmid: 22443187
references.citation: J Clin Endocrinol Metab. 2004 May;89(5):2078-84
references.pmid: 15126524
references.citation: J Neurosci Res. 2011 Apr;89(4):481-9
references.pmid: 21312223
references.citation: Diabetes Metab Res Rev. 2013 Jul 18;:
references.pmid: 23868462
references.citation: Neuropharmacology. 2014 Jan;76 Pt A:57-67
references.pmid: 23973293
references.citation: Lancet Neurol. 2012 Mar;11(3):261-71
references.pmid: 22341034
references.citation: Int J Obes (Lond). 2013 May;37(5):678-84
references.pmid: 22665137
references.citation: N Engl J Med. 2008 Jun 12;358(24):2560-72
references.pmid: 18539916
references.citation: Br J Pharmacol. 2012 Jul;166(5):1586-99
references.pmid: 22519295
references.citation: Stroke. 2003 Mar;34(3):688-94
references.pmid: 12624292
references.citation: Curr Alzheimer Res. 2011 Sep;8(6):666-77
references.pmid: 21679154
references.citation: J Neurochem. 2010 Nov;115(4):845-53
references.pmid: 20964688
references.citation: Exp Neurol. 2012 Dec;238(2):243-53
references.pmid: 22995601
references.citation: Age (Dordr). 2012 Oct;34(5):1211-24
references.pmid: 21901364
references.citation: FASEB J. 2009 Dec;23(12):4256-65
references.pmid: 19703933
references.citation: Lancet. 2014 Mar 22;383(9922):1068-83
references.pmid: 24315620
references.citation: Lancet Diabetes Endocrinol. 2015 Jan;3(1):75-89
references.pmid: 25163604
references.citation: Cardiovasc Diabetol. 2015 May 20;14:54
references.pmid: 25986579